Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage Cell Signaling Technology
PhosphoSitePlus
HomeAbout PhosphoSiteUsing PhosphoSiteCuration ProcessContact
NIH-logos NIGMS Logo NIAAA Logo NCI Logo NIH Logo
Curated Information Page
PubMed Id: 15475366 
This page summarizes selected information from the article referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2012,40:D261-70). To learn more about the scope of PhosphoSitePlus®, click here.
Zhang Y, Biggs JR, Kraft AS (2004) Phorbol ester treatment of K562 cells regulates the transcriptional activity of AML1c through phosphorylation. J Biol Chem 279, 53116-25 15475366
Only sites from this record are displayed on this page. Click on the protein name to open the protein page, and on the RSD number to open the site page. For the complete dataset, click the download button, on the right.
Download Sites

S276-p - AML1 iso8 (human) ▲
Orthologous residues
AML1 (human): S249‑p, AML1 iso2 (human): S249‑p, AML1 iso8 (human): S276‑p, AML1 (mouse): S249‑p, AML1 (rat): S249‑p
Characterization
 Methods used to characterize site in vivo:  [32P] bio-synthetic labeling, mutation of modification site
 Disease tissue studied:  leukemia, chronic myelogenous leukemia
 Relevant cell lines - cell types - tissues:  K562 (erythroid) [AML1 iso8 (human)]
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE ERK1 (human) pharmacological inhibitor of upstream enzyme
KINASE ERK2 (human) pharmacological inhibitor of upstream enzyme

S293-p - AML1 iso8 (human) ▲
Orthologous residues
AML1 (human): S266‑p, AML1 iso2 (human): S266‑p, AML1 iso8 (human): S293‑p, AML1 (mouse): S266‑p, AML1 (rat): S266‑p
Characterization
 Methods used to characterize site in vivo:  [32P] bio-synthetic labeling, mutation of modification site
 Disease tissue studied:  leukemia, chronic myelogenous leukemia
 Relevant cell lines - cell types - tissues:  K562 (erythroid) [AML1 iso8 (human)]
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE ERK1 (human) pharmacological inhibitor of upstream enzyme
KINASE ERK2 (human) pharmacological inhibitor of upstream enzyme
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
phorbol ester increase
PD98059 phorbol ester inhibit treatment-induced increase

T300-p - AML1 iso8 (human) ▲
Orthologous residues
AML1 (human): T273‑p, AML1 iso2 (human): T273‑p, AML1 iso8 (human): T300‑p, AML1 (mouse): T273‑p, AML1 (rat): T272‑p
Characterization
 Methods used to characterize site in vivo:  [32P] bio-synthetic labeling, mutation of modification site
 Disease tissue studied:  leukemia, chronic myelogenous leukemia
 Relevant cell lines - cell types - tissues:  K562 (erythroid) [AML1 iso8 (human)]
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE ERK2 (human) pharmacological inhibitor of upstream enzyme
KINASE ERK1 (human) pharmacological inhibitor of upstream enzyme
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
phorbol ester increase
PD98059 phorbol ester inhibit treatment-induced increase

S303-p - AML1 iso8 (human) ▲
Orthologous residues
AML1 (human): S276‑p, AML1 iso2 (human): S276‑p, AML1 iso8 (human): S303‑p, AML1 (mouse): S276‑p, AML1 (rat): S275‑p
Characterization
 Methods used to characterize site in vivo:  [32P] bio-synthetic labeling, mutation of modification site
 Disease tissue studied:  leukemia, chronic myelogenous leukemia
 Relevant cell lines - cell types - tissues:  K562 (erythroid) [AML1 iso8 (human)]
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE ERK1 (human) pharmacological inhibitor of upstream enzyme
KINASE ERK2 (human) pharmacological inhibitor of upstream enzyme
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
phorbol ester increase
PD98059 phorbol ester inhibit treatment-induced increase

S462-p - AML1 iso8 (human) ▲
Orthologous residues
AML1 (human): S435‑p, AML1 iso2 (human): S435‑p, AML1 iso8 (human): S462‑p, AML1 (mouse): S434‑p, AML1 (rat): S433‑p
Characterization
 Methods used to characterize site in vivo:  [32P] bio-synthetic labeling, mutation of modification site
 Disease tissue studied:  leukemia, chronic myelogenous leukemia
 Relevant cell lines - cell types - tissues:  K562 (erythroid) [AML1 iso8 (human)]
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE ERK2 (human) pharmacological inhibitor of upstream enzyme
KINASE ERK1 (human) pharmacological inhibitor of upstream enzyme
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
phorbol ester increase
PD98059 phorbol ester inhibit treatment-induced increase


Home  |  Curator Login With enhanced literature mining using Linguamatics I2E I2E Logo Produced by 3rd Millennium  |  Design by Digizyme
©2003-2013 Cell Signaling Technology, Inc.